Showing 4681-4690 of 5000 results for "".
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has b
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- Brodalumab Outperforms Ustekinumab in Head-to-Head Trialhttps://practicaldermatology.com/news/20141112-brodalumab_outperforms_ustekinumab_in_head-to-head_trial/2459070/New findings from the Phase III AMAGINE-3 trial suggest that the investigational IL-17 inhibitor brodalumab (Amgen/AstraZeneca) may be superior to ustekinumab in treating patients with moderate to severe psoriasis. In the study, investigators evaluated more than 1,800 patients who were randomized to
- Women's Rogaine 5% Minoxidil Topical Aerosol Receives FDA Approvalhttps://practicaldermatology.com/news/20141104-womens_rogaine_5_minoxidil_topical_aerosol_receives_fda_approval/2459075/The official launch to market of Women's Rogaine 5% Minoxidil Topical Aerosol, once-daily use treatment for Female Pattern Hair Loss containing 5 percent minoxidil in an elegant foam formula. Minoxidil is the only topical ingredient FDA-approved to help regrow hair. Women's Rogai
- Foamix Pharmaceuticals Will Host Key Opinion Leader Meeting and Webcast on November 4th in New York Cityhttps://practicaldermatology.com/news/20141029-foamix_pharmaceuticals_will_host_key_opinionleader_meeting_and_webcast_on_november_4th_in_new_york_city/2459077/Foamix Pharmaceuticals Ltd. will host a Key Opinion Leader breakfast on Tuesday, November 4, 2014 from 8:00am-9:30am Eastern Time in New York City. The meeting will feature key opinion leader Mark Lebwohl, MD, who leads a renowned dermatology program in the U.S., as the Sol and Clara Kes
- Nerium International Announces Creation of Scientific Advisory Boardhttps://practicaldermatology.com/news/20141027-nerium_international_announces_creation_of_scientific_advisory_board/2459078/Nerium International established a Scientific Advisory Board, comprised of the following scientists and dermatologists: Dr. Adam Friedman, Dr. Neal Bhatia, Dr. Mira Stotland, Marie Bertrand, Dr. Debra J. Wattenberg, and Dr. Karthik Krishnamurthy. The mission of the
- AmSpa Welcomes Cathy Christensen as Executive Director or Operations and Communicationshttps://practicaldermatology.com/news/20141009-amspa_welcomes_cathy_christensen_as_executive_director_or_operations_and_communications/2459089/Cathy Christensen, former editor of Skin Inc. magazine and conference director for the Face and Body events, is now Executive Director or Operations and Communications of AmpSpa. Christensen said, "I have been honored to have a role in serving the professional skin care industry's profes
- Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercializationhttps://practicaldermatology.com/news/20141008-coronado_biosciences_forms_subsidiary_to_acquire_and_license_dermatology_products_for_commercialization/2459090/Coronado Biosciences, Inc. has formed a wholly owned subsidiary called, Journey Medical Corporation (JMC) to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid respons
- Researchers to Present Gigapixel Whole-Body Camera at OSA Annual Meetinghttps://practicaldermatology.com/news/20141008-researchers_to_present_gigapixel_whole-body_camera_at_osa_annual_meeting/2459091/A new “gigapixel whole-body photographic camera” may provide an option for tracking changes in potentially cancer skin lesions. Duke University researchers who developed the imaging technology will presenting it at the The Optical Society's (OSA) 98th Annual Meeting, Frontiers in Optics, Oct. 19-23
- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti